Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1578-1586 , December 2009

Successful Stem Cell Remobilization Using Plerixafor (Mozobil) Plus Granulocyte Colony-Stimulating Factor in Patients with Non-Hodgkin Lymphoma: Results from the Plerixafor NHL Phase 3 Study Rescue Protocol

  • Ivana N. Micallef

      Affiliations

    • Mayo Clinic, Department of Internal Medicine, Division of Hematology Rochester, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Ivana Micallef, MD, Mayo Clinic College of Medicine, Mayo Clinic, 2300 First Street SW, Rochester, MN.
    • ,
  • Patrick J. Stiff

      Affiliations

    • Loyola University, Department of Medicine, Hematology/Oncology, Chicago, Illinois
    • ,
  • John F. DiPersio

      Affiliations

    • Washington University Department of Medicine, Oncology Division, St. Louis, Missouri
    • ,
  • Richard T. Maziarz

      Affiliations

    • Oregon Health Science University, Portland, Oregon
    • ,
  • John M. McCarty

      Affiliations

    • MCV Hospital, Bone Marrow Transplant Program, Richmond, Virginia
    • ,
  • Gary Bridger

      Affiliations

    • Genzyme Corporation, Cambridge, Massachusetts
    • ,
  • Gary Calandra

      Affiliations

    • Genzyme Corporation, Cambridge, Massachusetts

Received 24 June 2009 ,Accepted 7 August 2009.

References 

  1. Bashey A, Donohue M, Liu L, et al. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte macrophage colony-stimulating factor and granulocyte colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion. 2007;47:2153–2160
  2. Flomenberg N, Devine S, Dipersio J, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–1874
  3. Pavone V, Gaudio F, Guarini A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002;29:285–290
  4. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056
  5. Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica. 2008;93:405–412
  6. Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;26:471–481
  7. Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pretreated lymphoma patients: a matched-pairs analysis of 78 patients. Br J Cancer. 2000;82:278–282
  8. Weaver CH, Tauer K, Zhen B, et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother. 1998;7:241–249
  9. Goterris R, Hernandez-Boluda JC, Teruel A, et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant. 2005;36:847–853
  10. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant. 2004;33:997–1003
  11. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527:255–262
  12. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009;15:249–256
  13. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase 3 prospective randomized double-blind placebo-controlled trial of plerixafor (AMD3100) plus G-CSF versus placebo plus G-CSF for autologous stem cell mobilization and transplantation in patients with non-hodgkin's lymphoma. J Clin Oncol. 2009;Published ahead of print on august 31, 2009.
  14. Gazitt Y, Freytes CO, Callander N, et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother. 1999;8:173–183
  15. Perry AR, Watts MJ, Peniket AJ, et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant. 1998;21:1201–1205
  16. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338
  17. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant. 2009;43:909–917

 Financial disclosure: See Acknowledgments on page 1585.

PII: S1083-8791(09)00369-3

doi: 10.1016/j.bbmt.2009.08.005

Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1578-1586 , December 2009

Article Tools

* Image Usage & Resolution